OncologyTube Professional - Patients Click Here
AnnualMeeting2017
104,191 video views
Loading........
Description: Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Pembro...
02:15
H. Jack West, MD of Swedish Cancer Institute gives an overview of the use of gefinitib compared to standard chemotherapy (vinorelbine+cis​platin) as adjuvant treatment for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8500: Ge...
by:AnnualMeeting2017 | 973 views
02:22
H. Jack West, MD of Swedish Cancer Institute discusses the updated results of the KEYNOTE-021 study for patients with advanced nonsquamous non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9094: First-line carboplatin and pemetrexed (CP) with ...
by:AnnualMeeting2017 | 1007 views
01:54
H. Jack West, MD of Swedish Cancer Institute discusses an abstract that focused on the efficacy and safety of a third generation ALK inhibitor, lorlatinib, for ALK positive non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9006: Efficacy and safety of lorlatinib in patients (pts) with ALK+ no...
by:AnnualMeeting2017 | 1024 views
03:15
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ARCHER 1050 trial for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA9007: Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell ...
by:AnnualMeeting2017 | 786 views
02:45
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ALEX trial for ALK+ non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung c...
by:AnnualMeeting2017 | 1039 views
00:55
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take home of the POLLUX and CASTOR trials, which is the importance of early triplet therapy for relapsed patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plu...
by:AnnualMeeting2017 | 710 views
01:33
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology argues that the take-home message for the follow-up on the RESONATE trial is the role of ibrutinib for all types of CLL patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7510: Long-ter...
by:AnnualMeeting2017 | 854 views
01:19
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take-home message of the LATITUDE study at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diag...
by:AnnualMeeting2017 | 462 views
01:40
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked at daratumumab in combination with lenalidomide plus dexamethasone (DRd) and bortezomib plus dexamethasone in relapsed and refractory multiple myeloma. This was r...
by:AnnualMeeting2017 | 776 views
02:31
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the LATITUDE trial, a phase III trial on androgen deprivation therapy (ADT) with abiraterone in newly diagnosed, high-risk, metastatic prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago,...
by:AnnualMeeting2017 | 317 views

About AnnualMeeting2017


Links
Channel Url: